Viewing data from:

FINZALA

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | A210087 | TEVA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Finzala (2023)

Total Spending

$18K

Total Claims

184

Beneficiaries

Avg Cost/Unit

$1.95

Spending Trend

$5K(2022)→$18K(2023)

YoY Change:-24.8%

5yr CAGR:-24.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.02MG;1MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 7, 2020

No patent or exclusivity listings for this strength.